Bansinath M, Sequeira R P, Shukla V K, Mathur V S
Int J Clin Pharmacol Ther Toxicol. 1984 Jun;22(6):279-83.
Pretested mail survey questionnaires consisting of four close-ended, six open-ended questions and an "anonymous prescribing" exercise were sent to 612 members of the Cardiological Society of India. This was done to assess their opinion regarding generic prescribing, to record the incidence of generic prescribing for digoxin and furosemide and to evaluate the extent of comprehension of novel terminology like bioequivalence, generic equivalence and therapeutic equivalence. The majority of the responders opted for brand prescribing and mentioned that substitution by a pharmacist was not acceptable. The reputation of the firm, availability and ease of remembering the name, cost and impact of medical representative were, in descending order, the reasons for the option of a specific brand name. The innovator's brand of digoxin (Lanoxin) was prescribed by 59% while 37% wrote the generic name. Lasix was the most often prescribed (77%) brand of furosemide. Comprehension of the novel terms was not related to years of practice or to the place of practice. The need for evaluation of brands encountered by the prescriber in future studies on brand versus generic prescribing has been emphasized.
预先测试的邮件调查问卷被发送给印度心脏病学会的612名成员，问卷包含四个封闭式问题、六个开放式问题以及一项“匿名处方”练习。这样做是为了评估他们对通用名处方的看法，记录地高辛和呋塞米通用名处方的发生率，并评估对生物等效性、通用等效性和治疗等效性等新术语的理解程度。大多数受访者选择品牌处方，并表示药剂师进行替换是不可接受的。公司声誉、可用性、名称易记性、成本以及医药代表的影响，按降序排列，是选择特定品牌名称的原因。59%的人开了地高辛的原研药品牌（Lanoxin），而37%的人写了通用名。速尿最常被处方的品牌是Lasix（77%）。对新术语的理解与从业年限或执业地点无关。强调了在未来品牌与通用名处方的研究中，需要对开处方者遇到的品牌进行评估。
